news
First-in-class therapy shows potential for chronic fibrosis
A novel, first-in-class oral therapy showed meaningful improvement in over half of scleroderma patients in a Phase II trial for serious inflammatory and fibrotic diseases.
List view / Grid view
Scleroderma
news
First treatment for patients with rare lung disease approved
The FDA has approved the first treatment for interstitial lung disease associated with systemic sclerosis or scleroderma.
news
Orphan drug designation granted to Boehringer Ingelheim’s systemic sclerosis drug
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD...
news
Cytori launches managed access programme for ECCS-50 for scleroderma
12 January 2016 | By Victoria White
ECCS-50 is an autologous, adipose-derived cell therapy produced at the patient’s bedside and administered via a series of hand injections, in a single same-day procedure...
article
Biologics: Teamwork pays off in race to expand market for monoclonal antibodies
22 October 2012 | By Bahija Jallal, Executive Vice President, Research & Development, MedImmune
The first biologic drug – infliximab (Remicade) – was launched in 1998 with initial sales of USD 500 million per annum. By 2010, Reuters’ top 10 drugs by sales included five biologics (Remicade, Enbrel, Humira, Avastin and Humira) generating around USD 34 billion in revenue, including USD 7.4 billion from…
news
Bristol-Myers Squibb completes acquisition of Amira Pharmaceuticals
8 September 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc...
news
Bristol-Myers Squibb to acquire Amira Pharmaceuticals
21 July 2011 | By Bristol-Myers Squibb
Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company...
